M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
BeiGene gets expanded approval for Brukinsa in Brazil
Biotechnology company BeiGene (NASDAQ:BGNE) (HKEX:06160) (SSE:688235) announced on Thursday that Brukinsa (zanubrutinib) has been approved in Brazil as a treatment for rare blood cancers.
Regulators approved the use of Brukinsa for the treatment of adult patients with Waldenström's...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search